ACADIA Pharmaceuticals (ACAD) TD Cowen 46th Annual Health Care Conference summary

Revenue and growth outlook

• Projected $1.7 billion in net sales by 2028, split between NUPLAZID ($1B) and DAYBUE ($700M).

• NUPLAZID guidance assumes 12% annual growth through 2027, driven by expanded field force and marketing.

• DAYBUE expected to grow 20% in 2024, with penetration rising from 27% to early 30s by year-end.

• DAYBUE STIX, a new formulation, aims to unlock additional patients and improve adherence.

• International growth for DAYBUE supported by named patient programs outside the U.S.

Commercial strategy and field force expansion

• NUPLAZID field force increased by 30%, expanding reach from 7,000 to 11,000 physicians, including more PCPs.

• Strategy targets earlier intervention in psychosis, with 40% of scripts from new prescribers in the past year.

• Smaller territories and more frequent engagement expected to drive further growth.

Pipeline and clinical development

• Remlifanserin (204) phase II top-line data expected August–October; study focuses on Alzheimer's disease psychosis.

• Phase II/III design uses SAPS H+D as primary endpoint, with success defined by efficacy, safety, and tolerability.

• Phase III will be optimized based on phase II results; potential for pivotal study if highly significant.

• Lewy Body Dementia phase II study underway, leveraging biological and clinical rationale from prior data.